Transcrocetinate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Transcrocetinate API 27876-94-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Transcrocetinate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Transcrocetinate
- Synonyms:
- 8,8'-diapo-8,8'-carotenedioic acid , 8,8'-diapo-ψ,ψ-carotenedioic acid , 8,8'-diapocarotenedioic acid , Crocetin , trans-crocetin
- Cas Number:
- 27876-94-4
- DrugBank number:
- DB05974
- Unique Ingredient Identifier:
- 20TC155L9C
General Description:
Transcrocetinate, identified by CAS number 27876-94-4, is a notable compound with significant therapeutic applications. Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in cancer/tumors (unspecified), hemorrhage, hypoxia, respiratory failure, and strokes. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Transcrocetinate functions by: Trans sodium crocetinate is a novel drug, which has been shown to increase whole-body oxygen consumption during hemorrhagic shock. It works by increasing the diffusion rate of oxygen through plasma rather than on a specific symptom of hemorrhagic shock and has been suggested as a general treatment for hypoxemia. Thus it could also be beneficial for treating respiratory insufficiencies. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Categories:
Transcrocetinate is categorized under the following therapeutic classes: Anticarcinogenic Agents, Antineoplastic Agents, Antioxidants, Compounds used in a research, industrial, or household setting. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Transcrocetinate is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
